Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid TumorsJulius Strauss, James L. Gulley, Christoph Helwig et al.|Clinical Cancer Research|2018Cited by 415
Activity of durvalumab plus olaparib in metastatic castration-resistant prostate cancer in men with and without DNA damage repair mutationsFatima Karzai, William L. Dahut, E. Hitt Nichols et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 312
Adjuvant Pembrolizumab versus Observation in Muscle-Invasive Urothelial CarcinomaAndrea B. Apolo, Jonathan E. Rosenberg, Michael J. Morris et al.|New England Journal of Medicine|2024Cited by 145